Dividend Overview
Dividend Yield
—
Dividend / Share
—
Jupiter Neurosciences Inc
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.
Current Price
$0.24
+16.93%Dividend Yield
—
Dividend / Share
—
Market Cap
$7.06M
P/E Ratio
-0.77
Forward P/E
—
EPS
$-0.25
PEG Ratio
-0.04
Book Value
$-0.06
Dividend Yield
—
Profit Margin
-22690.83%
ROE
—
Jupiter Neurosciences Inc (JUNS) dividend analysis including yield, payout history, and sustainability metrics.
P/E ratio: -0.77. Profit margin: -22690.83%. Free cash flow: $-5.41M. This page shows Jupiter Neurosciences Inc's dividend overview, key metrics, historical payout data, and dividend safety assessment to help income-focused investors evaluate the sustainability of dividend payments.
GoodMoat's dividend analyzer evaluates payout ratios, earnings coverage, and free cash flow coverage to determine how well supported Jupiter Neurosciences Inc's dividend payments are. Use this analysis alongside the company's financial statements and quality score to make informed income-investing decisions.